FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.
FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
Published ·
Keep reading
